Brivaracetam
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Brivaracetam
- Pharmacist Assessment Report
- Brivaracetam: antiseizure medicine (SV2A ligand) → beta-ketothiolase deficiency (beta-ketothiolase deficiency)
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Brivaracetam: antiseizure medicine (SV2A ligand) → beta-ketothiolase deficiency (beta-ketothiolase deficiency)
One-Sentence Summary
Brivaracetam is an antiseizure medicine that is currently marketed in Canada. The TxGNN model predicts it may be effective for beta-ketothiolase deficiency, with a prediction score of 0.9914. No clinical trials or publications in the data compiled for this report support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | beta-ketothiolase deficiency |
| TxGNN Prediction Score | 0.9914 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 14 of 14) |
| Number of DINs | 14 (marketed: 14) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for brivaracetam are not available in the data compiled for this report. Brivaracetam is an antiseizure medicine, and its use is established in seizure disorders.
Beta-ketothiolase deficiency is an inherited metabolic disorder affecting ketone body production and isoleucine breakdown. Brivaracetam has no known mechanistic link to this pathway beyond possible symptomatic control of seizures that may occur during metabolic crises. The high score appears to reflect the model’s pattern-based associations rather than demonstrated biology. This prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02452960 | BRIVLERA | Not recorded | Not recorded |
| 02452987 | BRIVLERA | Not recorded | Not recorded |
| 02538679 | APO-BRIVARACETAM | Not recorded | Not recorded |
| 02539306 | AURO-BRIVARACETAM | Not recorded | Not recorded |
| 02538687 | APO-BRIVARACETAM | Not recorded | Not recorded |
The list shows 5 of the valid single-ingredient authorizations (all 14 are valid).
Safety Considerations
- Drug Interactions: 69 interactions were identified. Examples at moderate level include morphine, dronabinol, nabilone, metoclopramide, promethazine, clopidogrel, ethanol, opium, sibutramine, diphenoxylate and difenoxin. Minor-level examples include omeprazole, pantoprazole, esomeprazole, lansoprazole, cilostazol, tolbutamide and chlorpropamide.
Please also refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature and no plausible mechanistic link, so it remains a model-only hypothesis (L5).
To proceed, the following is needed:
- Mechanism-of-action data and a plausible biological rationale linking brivaracetam to ketone body or isoleucine metabolism
- Preclinical or case-level evidence directly studying beta-ketothiolase deficiency
- Package insert warnings and contraindications from Health Canada for safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.